- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Country Report: Egypt
Pharmaceutical Executive
In the middle of new reforms, and with its political turmoil well in the past, Egypt is striving to open the door to a brave new era of healthcare provision, where improving public healthcare has been assigned priority status.
Gaining Traction
After successive revolutions and a period of political turmoil between 2011 and 2013, Egypt is currently enjoying a period of relative stability, with President Abdel Fattah El-Sisi officially taking power in 2014 and gaining reelection in a landslide victory in 2018. Under his auspices, an extensive set of economic reforms has commenced: most notably the 2016 decision to unpeg the national currency from the US dollar so as to float the Egyptian Pound, and the introduction of a new investment law in 2017.
Moreover, improving public healthcare has been assigned priority status, with wellness considered one of the pillars of the cabinet’s human capital development goals. Objectives here include the launch of the Universal Healthcare Act and various national campaigns, such as the 100 Million Seha campaign to eradicate hepatitis C in the country. In the light of these reforms, Egypt is striving to open the door to a brave new era of healthcare provision, with all the fresh businesses opportunities that this presupposes.
To view the full article on Egypt’s life sciences and healthcare markets, produced by Focus Reports and featured in Pharm Exec's July 2019 issue, click
here(cycle down to page 38).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
